DRG Acquires DIMA Diagnostica from bioMérieux
DRG Instruments GmbH in Marburg, Germany, a wholly owned subsidiary of the DRG International Group headquarted in Mountainside, New Jersey, USA, announces the acquisition of diagnostic assets of DIMA Corporation, a subsidiary of bioMérieux, in Lyon, France. With the purchase, DRG will expand its market share of Elisa production and distribution internationally, cementing its place as one of the world's leading diagnostic testing supply manufacturers.
DRG Instruments will acquire the microtiter plate Elisa production, including existing finished stock, raw materials, from DIMA, which is based in Germany. Both companies will cooperate until the end of 2010 to ensure a seamless transition of the scope of business in the interest of the end-user customers.
With over $50 million in sales and operations in more than 110 countries, DRG is at the forefront of the diagnostic testing industry.
"This purchase is an exciting step in an already stellar year for DRG International," said Cyril Geacintov, Ph.D., CEO and President of DRG International. "Our Elisa production and instrument development continue to position us as a leader in the industry, serving our customers to the fullest, with innovative, top-quality products."
DRG, a company known for quality and excellent service will supply all existing customers and distributors with DIMA products under the DIMA label until the end of the year. As of January 1, 2011, production of DIMA products will continue to be available under the DRG label in accordance with contractual agreements between bioMérieux and DRG International, Inc.
For more information, please contact DRG Instruments GmbH +49-6421-17000 or visit www.drg-instruments.de.